Houston cell therapy company launches second-phase clinical trial

fighting cancer

March Biosciences is testing its MB-105 cell therapy in a Phase 2 clinical trial for people with difficult-to-treat cancer. Photo via march.bio

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

From Your Site Articles
Researchers from Baylor College of Medicine and the University of Houston have developed a new blood-filtering machine that poses fewer risks to pediatric patients with hyperleukocytosis. Photo courtesy UH.

UH, Baylor researchers make breakthrough with new pediatric leukemia treatment device

childhood cancer

A team of Houston researchers has developed a new microfluidic device aimed at making treatments safer for children with hyperleukocytosis, a life-threatening hematologic emergency often seen in patients with leukemia.

Dr. Fong Lam, an associate professor of pediatrics at Baylor College of Medicine and a pediatric intensive care physician at Texas Children’s Hospital, partnered with Sergey Shevkoplyas, a professor of biomedical engineering at UH, on the device that uses a large number of tiny channels to quickly separate blood cells by size in a process called controlled incremental filtration, according to a news release from UH.

They tested whether performing cell separation with a high-throughput microfluidic device could alleviate the limitations of traditional conventional blood-filtering machines, which pose risks for pediatric patients due to their large extracorporeal volume (ECV), high flow rates and tendency to cause significant platelet loss in the patient. The results of their study, led by Mubasher Iqbal, a Ph.D. candidate in biomedical engineering at UH, were published recently in the journal Nature Communications.

“Continuously and efficiently separating leukocytes from recirculating undiluted whole blood — without device clogging and cell activation or damage — has long been a major challenge in microfluidic cell separation,” Shevkoplyas said in a news release. “Our study is the first to solve this problem.”

Hyperleukocytosis is a condition that develops when the body has an extremely high number of white blood cells, which in many cases is due to leukemia. According to the release, up to 20 percent to 30 percent of patients with acute leukemia develop hyperleukocytosis, and this places them at risk for potentially fatal complications.

The new device utilizes tiny channels—each about the width of a human hair—to efficiently separate blood cells through controlled incremental filtration. According to Lam, the team was excited that the new device could operate at clinically relevant flow rates.

The device successfully removed approximately 85 percent of large leukocytes and 90 percent of leukemic blasts from undiluted human whole blood without causing platelet loss or other adverse effects. It also operates with an ECV that’s about 1/70th of conventional leukapheresis machines, which makes it particularly suitable for infants and small children.

“Overall, our study suggests that microfluidics leukapheresis is safe and effective at selectively removing leukocytes from circulation, with separation performance sufficiently high to ultimately enable safe leukapheresis in children,” Shevkoplyas said in the release.

March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. Photo via Getty Images

Clinical-stage Houston cell therapy company closes $28.4M oversubscribed series A

cha-ching

An emerging biotech company in Houston has closed its series A with outsized success.

March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. The company has now raised more than $51 million in total.

Last year, March Biosciences announced its strategic alliance with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience. CEO Sarah Hein met her co-founder, Max Mamonkin, at the TMC Accelerator for Cancer Therapeutics. Along with fellow co-founder Malcolm Brenner, March Biosciences launched from the Center for Cell and Gene Therapy (Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital). Its goal is to fight cancers that have been unresponsive to existing immunotherapies using its lead asset, MB-105.

An autologous CD5-targeted CAR-T cell therapy, MB-105 is currently in phase-1 trials in patients with refractory T-cell lymphoma and leukemia. The treatment is showing signs of being both safe and effective, meriting a phase-2 trial that will begin early next year. The funds raised from the series A will help to finance the Phase 2 clinical development of MB-105 to expand on the existing data with optimized manufacturing processes.

“This oversubscribed financing enables us to advance our first-in-class CAR-T therapy, MB-105, into a Phase 2 trial for T-cell lymphoma – an indication with an exceptionally poor prognosis and few treatment options,” says Hein. “With the support and confidence of our investors, we are not only advancing our lead program but also expanding our pipeline, underscoring our commitment to delivering best-in-class therapies to patients that can change the treatment paradigm for these challenging cancers.”

But that’s not the only exciting news that Hein and her associates have to report. March Biosciences has recently partnered with cell therapy venture studio, Volnay Therapeutics. Led by highly experienced cell therapy development veterans, the March Biosciences team will work to develop a scalable manufacturing process for MB-105 that will lead to commercialization. Volnay co-founder and CEO Stefan Wildt, who held key R&D leadership positions in cell and gene therapy units at Novartis and Takeda, has also joined the board of March Biosciences. The board of directors is also welcoming Cassidy Blundell of Mission BioCapital and Owen Smith of 4BIO Capital.

“The team at March Biosciences is leveraging powerful science and promising clinical data to tackle cancers with significant unmet need,” says Blundell, a partner at Mission BioCapital. “We're excited to support their journey and believe their focused approach with MB-105 could lead to significant breakthroughs in the CAR-T space.”

The Houston-born company, which is a finalist for the 2024 Houston Innovation Awards, continues to accelerate quickly, in part thanks to its home base. After all, existing local investors like TMC Venture Fund also participated in the new raise. As Hein said last year, “Working with partners here in Houston, we have all the pieces and the community rises to the occasion to support you.”

Rice biochemist Natasha Kirienko and MD Anderson physician-scientist Marina Konopleva made the striking discovery. Photo by Jeff Fitlow

Rice and MD Anderson researchers discover exciting new leukemia treatment

big win

Rice University and MD Anderson researchers have just discovered a potential one-two punch that could, they hope, knock out an insidious disease.

A recent study in the journal Leukemia centers on potential new drugs that, with the help of other medications, can thwart leukemia cells.

Specifically, Rice biochemist Natasha Kirienko and MD Anderson physician-scientist Marina Konopleva screened some 45,000 small-molecule compounds to find a few that targeted mitochondria, according to Rice press materials.

In this innovative new study, the team selected eight of the most promising compounds, identified between five and 30 closely related analogs for each, and conducted tens of thousands of tests to systematically determine how toxic each analog was to leukemia cells. This was measured both when administered individually or in combination with existing chemotherapy drugs like doxorubicin, notes a release.

Previously, Kirienko’s lab had shown the eight compounds targeted energy-producing machinery inside cells called mitochondria. Mitochondria, which work nonstop in every living cell, wear out with use. The chosen eight compounds induce mitophagy, which can be described as how cells decommission and recycle deficient and used-up.

Notably, during times of extreme stress, cells can temporarily forgo mitophagy for an emergency energy boost. Previous research has shown leukemia cells have far more damaged mitochondria than healthy cells and are also more sensitive to mitochondrial damage than healthy cells.

Thus, Kirienko and Konopleva reasoned that mitophagy-inducing drugs might weaken leukemia cells and make them more susceptible to chemotherapy. Synergy — using two or more drugs in treatment — is key.

“The point of synergy is that there are concentrations, or dosages, where a single drug doesn't kill,” Kirienko said. “There is no death of healthy cells or cancer cells. But administering those same concentrations in combination can kill a considerable amount of cancer cells and still not affect healthy cells.”

The team tested the toxicity of its mitophagy-inducing compounds and combinations against acute myeloid leukemia (AML) cells, the most commonly diagnosed form of the disease. They then tested the six most effective AML-killing compounds against other forms of leukemia, finding that five were also effective at killing acute lymphoblastic leukemia (ALL) cells and chronic myelogenous leukemia (CML) cells.

Studies found all the mitophagy-inducing drugs caused far less harm to healthy cells.

Finally, the researchers tested one of the most effective mitochondria-targeting compounds, PS127E, using a cutting-edge technique called a patient-derived xenograft (PDX) model. Also referred to as a “mouse clinical trial,” mice are implanted with cancer cells from a leukemia patient. As the cells grow, the mouse is exposed to a drug or combination of drugs as a closer-than-cells test of the treatment’s effect.

Importantly, PDX tests on one compound, PS127E, showed it was effective at killing AML cells in mice, Rice notes, signaling promising news.

“Although this is very promising, we’re still some distance from having a new treatment we can use in the clinic,” Kirienko added. “We still have a lot to discover. For example, we need to better understand how the drugs work in cells. We need to refine the dose we think would be best, and perhaps most importantly, we need to test on a wide variety of AML cancers. AML has a lot of variations, and we need to know which patients are most likely to benefit from this treatment and which are not. Only after we’ve done that work, which may take a few years, would we be able to start testing in humans.”

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

New manufacturing facility breaks ground at NASA’s Johnson Space Center

making space

HITT Contracting has broken ground on NASA’s Applied Spaceflight Fabrication Facility (ASFF) at Johnson Space Center, the Washington, D.C.-based construction firm announced late last month.

The project, known as Building 70, will house a high-bay machine shop to support component production for future NASA space missions, according to HITT. The 37,625-square-foot building is the first part of a larger goal to create an engineering complex that unites assembly space, lab capabilities and manufacturing at JSC. It will consolidate machining equipment and operations that are currently spread across multiple campus buildings into one location.

The project broke ground in October at JSC’s Historic District. The Houston Business Journal reports construction is expected to wrap in August of 2028.

“This project will modernize facilities that support America’s space missions,” PJ Ross, chief financial officer at HITT, said in a LinkedIn post. “Proud of our team and partners as we begin construction that will advance aerospace testing and innovation.”

HITT Contracting is one of seven companies awarded infrastructure contracts by NASA earlier this year for work at JSC. According to NASA, the construction contracts “[support] up to $300 million in upgrades to mission‑support facilities, utilities, and equipment across the NASA Johnson campus.”

Construction Drive reports that HITT will also renovate Building 13 South on the JSC campus as part of the $300 million initiative.

“Building for precision manufacturing starts with understanding how the space needs to perform,” Todd Hudson, vice president at HITT Contracting, added in the release. “Our team brings the technical expertise and collaborative approach to deliver a facility that meets the Johnson Space Center’s needs today and supports the next generation of spaceflight innovation. We’re proud to continue our partnership with NASA.”

NASA also recently announced awards as part of its expanded Moon Base exploration, science and infrastructure capabilities. Houston-based Intuitive Machines and seven other spacetech companies, including SpaceX, Blue Origin and Firefly Aerospace, were selected to receive funding.

The awards are part of the next phase of NASA’s CLPS (Commercial Lunar Payload Services) initiative, which will grant the companies a combined total of up to $10 billion over 10 years.

Intuitive Machines and Webster-based MEI Technologies were also awarded contracts this past summer from NASA to develop robots for exploring the surface of Mars. Read more here.

Meet 6 mentors guiding Houston’s next generation of startup founders

meet the finalists

Houston’s thriving startup ecosystem is supported by a network of experienced leaders who work behind the scenes, investing their time and knowledge to help the next generation of entrepreneurs succeed.

As part of the 2026 Houston Innovation Awards, the Mentor of the Year category will honor an individual who dedicates their time and expertise to guide and support budding entrepreneurs. They support promising startups in the medical tech, digital health, clean energy, hardware sectors and more.

Read more about these businesses, their founders and their breakthrough technologies below. The 2026 winners will be announced on InnovationMap.com in mid-November.

Al Danto, Rice University

Al Danto is a senior lecturer in entrepreneurship at Rice University. He mentors undergraduate and graduate students at Rice and through the university's Liu Idea Lab for Innovation and Entrepreneurship (Lillie). He's also involved in the Houston Entrepreneurs Organization and Rice Veterans' Business Battle.

"[Mentoring] is very rewarding and fulfilling," Danto says. "[It] helps to me to pay back full circle over the incredible mentors I have had."

Eric Rubenstein, New Climate Ventures

Eric Rubenstein is managing partner at New Climate Ventures. He mentors startups through the clean energy-focused early-stage VC firm and also through the Breakthrough Energy Fellowship, Activate, Greentown Labs and Yale Ventures. Rubenstein has worked with numerous startups and Innovation Awards finalists, including Solidec, Rheom Materials, Bairitone Health, Pattern Materials and many others.

"Being a mentor is an important part of an innovation ecosystem," Rubenstein says. "Seeing founders succeed is rewarding, particularly if what they are building will meaningfully contribute to society. It is a way to give back that also builds community, as mentorship often involves introducing founders to other mentors, to potential investors and to potential customers. Just like the adage 'it takes a village' is used in reference to raising a child, the same adage applies to building a startup. That’s why we say 'let’s build.' Let’s build is inclusive because we do it together, as a community, even if the founders need to execute on a daily basis to make their vision a reality."

Jeremy Pitts, Activate

Jeremy Pitts serves as managing director of Activate Houston, which launched in Houston in 2024. He was one of the founders of Greentown Labs in the Boston area and served in a leadership role for the organization between 2011 and 2015. Through Activate, he has mentored numerous impactful startups and Innovation Awards finalists, including Solidec, Coflux Purification, Bairitone Health, Newfound Materials, Deep Anchor Solutions and others.

"Mentorship to me is all about selflessly supporting a person," Pitts says. "The person comes first--if you're not supporting the person, then their business needs don't matter. I'm there not to answer questions for people, but to help them gain the confidence and the capability to solve problems on their own. I am successful when my mentees are successful and happy, regardless of what their personal definition of success might look like."

Joe Alapat, Liongard

Joe Alapat founded and serves as chief strategy officer at Houston software company Liongard. He founded Startup Circle Houston and co-hosts Cybersecurity Circle, which both meet regularly at The Ion. He participates in Mercury Fund Day and has also mentored through Impact Hub Houston. He's worked with founders of FlowCare, Unytag, STEAM OnDemand, Lokum and many other early-stage startups.

"I compare being a mentor for startup founders to the Montessori method. ... Mentoring should not involve telling a founder what to do," Alapat says. "I see it as a founder whisperer approach that seeks to challenge the founder to think through their journey through different lenses and go on a journey of self-discovery while discovering the true market pain they are seeking to solve. The cherry on top is that the mentor gains as much as the mentee, so learning is happening for both. Ultimately, the meter of achievement with mentoring is seeing visible progress with the maturity of the founder and the degree of traction for their startup."

Kyle Judah, Rice University's Liu Idea Lab for Innovation & Entrepreneurship

Kyle Judah is the executive director of Lilie, where he mentors pre-seed student startups. He also mentors through organizations like TEX-E, Greentown Labs, Activate and previously with MassChallenge. Some of the startups he's mentored include Helix Earth Technologies, Tierra Climate, Solidec, HexaSpec, SteerBio and many others.

"[Being a mentor] means helping to ensure that the most people possible have the best shot possible at making their company a successful reality," Judah says. "It means, at its root, opening the aperture for what is possible for people, by believing in them before anyone else even understands what their ambitions are. Because belief is the most infectious thing in the world. And before digging into the work in the trenches, most times founders need to kickstart their journey by having someone from the outside believe in them, when there's no real evidence to support that belief. So I guess, mentorship is a pure form of entrepreneurial faith."

Rachel Bickham, Bickham Services Unlimited LLC

Rachel Bickham is CEO of Bickham Services Unlimited, through which she mentors founders across a range of business stages and industries. She founded the organization in 2017. Bickham also mentors through The Affirmed Entrepreneur, a mentorship platform that she also launched. In 2024, she also began mentoring through the Goldman Sachs One Million Black Women: Black in Business program. Some of the startups she has worked with included Elaine Transportation, Nakira's World and NP Skills Made Easy, among others.

"Being a mentor means helping someone see what is possible while being honest about what it will take to get there," Bickham says. "It is not about giving generic advice or telling entrepreneurs what they want to hear. Sometimes mentorship means offering encouragement, and sometimes it means asking difficult questions that help someone avoid an expensive mistake. In both situations, my responsibility is to listen, share what I have learned, and help the entrepreneur make an informed decision. ... Being a mentor also means opening doors when I can—making introductions, inviting entrepreneurs into rooms they may not have entered on their own, and helping them build relationships that can change the direction of their businesses. It also means holding them accountable for what they said they wanted to accomplish. I do not measure successful mentorship by how often someone returns to me for an answer. I measure it by whether they become more confident, more strategic, and better equipped to make decisions on their own."

3 Houston incubators and accelerators fueling the growth of local startups

Meet the finalists

It takes a village to launch a business. That's where Houston's network of incubators and accelerators can step in, providing the resources, mentorship and community needed to push a fledgling company forward.

As part of our 2026 Houston Innovation Awards, the Incubator/Accelerator of the Year category honors a local organization that is championing and fueling the growth of Houston startups.

Three incubators and accelerators have been named finalists for the 2026 award. They support startups ranging from hard-tech companies to food and youth concepts.

Read more about these organizations below. The 2026 winners will be announced on InnovationMap.com in mid-November.

Activate

Hard tech incubator Activate supports scientists in "the outset of their entrepreneurial journey." The Houston hub was introduced in 2024, and joins others in Boston, New York, and Berkley, California—where Activate is headquartered. It named its third Houston cohort this summer.

The two-year program graduated its first class of Houston fellows in 2026 and saw its first alumni IPO from Houston-based Fervo Energy, which previously participated in a Berkley cohort. Nationally, it has supported 346 fellows and 276 companies since 2015. Those companies have raised more than $6 billion in follow-on funding, according to Activate. In Houston, it has supported Houston startups like Solidec, FlowCellutions and Orbital Arc. Activate Houston is led by managing director Jeremy Pitts, who co-founded Greentown Labs in Boston. It is based out of the Ion.

Impact Hub Houston

Impact Hub Houston supports early-stage ventures at various stages of development through innovative programs that address pressing societal issues. The nonprofit organization supports social impact startups through mentorship, connections and training opportunities.

There are more than 110 Impact Hubs globally with members spanning 72 countries. Launched in 2018, Impact Hub Houston says its membership tripled by the beginning of 2026. This year brought major milestones for the community, including the launch of its Ideas to Impact Accelerator, which supported 11 founders across the health, education, food systems, civic technology and workforce development sectors. It also received funding from more than 20 international Impact Hubs to develop SYNC, a collaboration platform that 25 Impact Hubs across five continents have committed to pilot. The organization has worked with local startups including Myoviva Health, The Change Lab and INNERVERSE Inc.

MarMo Innovation

Galveston-based business incubator MarMo Innovation is focused on removing barriers to entrepreneurship. It aims to provide affordable space, education, mentorship, market access, connections and real-world opportunities that help entrepreneurs move from idea to launch to sustainable growth. The "industry-agnostic" incubator was founded in 2022 and is led by Executive Director Erica Delgadillo.

This year, the organization moved from primarily serving as a coworking and community space into a more comprehensive entrepreneurial incubator by expanding its MarMo Market, MarMo Market Jr. and Lunch LineUp programs. A major focus for MarMo is food entrepreneurship. It is developing an Incubator Kitchen, which MarMo says will support programs like its Cottage to Commercial Bootcamp and Food Biz 101. The organization also expanded its board this year and says it is diversifying its revenue through memberships, events, markets, equipment and space rentals, sponsorships, grants and new entrepreneurial programming.

View All Listings